n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Osteoarthritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, H; Gao, L; Jiao, G; Li, T; Liu, L; Ma, T; Song, X; Wang, X; Zhang, Z | 1 |
| Atar, E; Bar-Yehuda, S; Barer, F; Castel, D; Cohen, S; Del Valle, L; Fishman, P; Ochaion, A; Patoka, R; Perez-Liz, G; Piña-Oviedo, S; Rath-Wolfson, L; Zozulya, G | 1 |
2 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Osteoarthritis
| Article | Year |
|---|---|
CF101 alleviates OA progression and inhibits the inflammatory process via the AMP/ATP/AMPK/mTOR axis.
Topics: Adenosine; Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Cartilage, Articular; Chondrocytes; Collagen Type II; Disease Models, Animal; Inflammation; Osteoarthritis; Rats; TOR Serine-Threonine Kinases | 2022 |
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Apoptosis; Cartilage, Articular; Disease Models, Animal; Inflammation; Iodoacetates; Male; NF-kappa B; Osteoarthritis; Rats; Rats, Wistar; Signal Transduction | 2009 |